Analyst Price Target is $11.33
▲ +1,998.77% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for ASLAN Pharmaceuticals in the last 3 months. The average price target is $11.33, with a high forecast of $15.00 and a low forecast of $9.00. The average price target represents a 1,998.77% upside from the last price of $0.54.
Current Consensus is
Buy
The current consensus among 3 investment analysts is to buy stock in ASLAN Pharmaceuticals. This Buy consensus rating has held steady for over two years.
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal antibody that targets the IL-13 receptor a1 subunit which is being developed for the treatment of atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune diseases. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.
Read More